SCHEMBL3450951

SCHEMBL3450951

Clc1cc(Nc2ccc3c(c2)OCO3)nc(-c2ccccc2)n1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 4/20 0.63
ABCB1 P08183 3/20 0.63
ABCC1 P33527 2/20 0.63
PTGS2 P35354 3/20 0.52
ADORA2A P29274 5/20 0.47
ADORA1 P30542 5/20 0.47
ADORA3 P0DMS8 4/20 0.47
RHOA P61586 1/20 0.46
MEN1 O00255 5/20 0.46
KMT2A Q03164 5/20 0.46
NPC1 O15118 4/20 0.46
RAB9A P51151 4/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
PKM P14618 1/20 0.46
USP2 O75604 2/20 0.46
CYP1A2 P05177 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2D6 P10635 2/20 0.46
ALOX15 P16050 2/20 0.46
MAPK1 P28482 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5486573 0.83 ABCG2 (0.61) ABCG2ABCB1ABCC1PTGS2ADORA2A
SCHEMBL18177441 0.79 POLA1 (0.61) PTGS2MEN1KMT2ANPC1RAB9A
SCHEMBL3451724 0.78 HTT (0.58) ABCG2ABCB1ABCC1PTGS2RHOA
SCHEMBL3450825 0.78 AURKA (0.58) ABCG2ABCB1ABCC1PTGS2KMT2A
SCHEMBL13111031 0.78 ABCG2 (0.54) ABCG2ABCB1ABCC1PTGS2ADORA2A
SCHEMBL13127066 0.76 ABCG2 (0.54) ABCG2ABCB1ABCC1MEN1KMT2A
SCHEMBL4133787 0.75 LMNA (0.52) PTGS2MEN1KMT2ANPC1RAB9A
SCHEMBL13110702 0.75 ADORA1 (0.66) ABCG2ABCB1ABCC1PTGS2ADORA2A
SCHEMBL5192222 0.74 LMNA (0.43) ABCG2ABCB1ABCC1PTGS2MEN1
SCHEMBL5481520 0.73 ESR1 (0.64) ABCG2ABCB1ABCC1ADORA3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1796673-A2 NOVEL PYRIMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM Reddy US Therapeutics, Inc. (US) 2007-06-20 EP claimed
US-20060084645-A1 Novel pyrimidine compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2006-04-20 US claimed
WO-2006034473-A2 NOVEL PYRIMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM REDDY US THERAPEUTICS, INC. (US) 2006-03-30 WO claimed
US-7820654-B2 Pyrimidine compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2010-10-26 US disclosed
US-7820654-B2 Pyrimidine compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2010-10-26 US disclosed
US-7820654-B2 Pyrimidine compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2010-10-26 US disclosed
US-20060084645-A1 Novel pyrimidine compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2006-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084645-A1 Novel pyrimidine compounds, process for their preparation and compositions containing them UMPS, DPYD, TYMS ABCG2 566/4885ABCB1 2853/4885ABCC1 937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.